All relevant data are within the manuscript.

Introduction {#sec001}
============

Pancreatic cancer is associated with a high mortality rate worldwide. Although the global incidence is relatively low (about 8/100000 persons per year) \[[@pone.0211291.ref001]\], the 5-year survival rate is less than 5%. The poor survival rate is, in part, due to late detection of advanced stage disease, and thus, methods for early and accurate diagnosis of pancreatic cancer would help to improve outcomes for these patients. Currently, the diagnosis of pancreatic cancer is mainly based on imaging analyses, including computed tomography (CT) and magnetic resonance imaging (MRI). Unfortunately, even these imaging modalities are ineffective in some cases of pancreatic cancer \[[@pone.0211291.ref002]\]. Therefore, the identification of a reliable biomarker for pancreatic cancer diagnosis and prognosis has clinical significance.

Genome changes and self-sufficiency in growth signals are among the essential alterations that lead to malignant proliferation \[[@pone.0211291.ref003]\]. FAM64A, also referred to as PICALM Interacting Mitotic Regulator (gene symbol, *PIMREG*) \[[@pone.0211291.ref004]\], was first identified as a CALM (Clathrin Assembly Lymphoid Myeloid leukemia) interacting protein, expressed in response to mitogens. Expression of FAM64A influences the subcellular localization of CALM/AF10 and antagonizes the transactivation function of the leukemic fusion protein \[[@pone.0211291.ref005]--[@pone.0211291.ref007]\]. As a marker of cell proliferation, FAM64A protein expression is cell cycle-dependent \[[@pone.0211291.ref006], [@pone.0211291.ref008]\], and its expression level has been studied as a potential biomarker in several cancers in recent years \[[@pone.0211291.ref006], [@pone.0211291.ref009]--[@pone.0211291.ref012]\]. However, the potential roles of *FAM64A* expression in the diagnostic and prognostic evaluation of patients with pancreatic cancer have not yet been determined.

In the present study, we compared *FAM64A* mRNA expression between pancreatic cancer patients and healthy individuals. From an analysis of the diagnostic value of *FAM64A*, we divided patients into high and low *FAM64A* expression groups and searched for correlations between *FAM64A* expression and clinical features of pancreatic cancer as well as with patients' overall survival (OS) and recurrence-free survival (RFS). Gene set enrichment analysis (GSEA) was performed to identify the signaling pathways related to the regulatory mechanism of *FAM64A*. Our results indicate that *FAM64A* may be a useful biomarker for the diagnosis and prognosis of pancreatic cancer.

Materials and methods {#sec002}
=====================

Data mining {#sec003}
-----------

Level 3 expression data were downloaded from The Cancer Genome Atlas (TCGA) database and estimated as log2(x+1) transformed RSEM normalized counts. Clinical information was also obtained from TCGA database. Expression data for normal pancreatic tissue was download from The Genotype-Tissue Expression (GTEx) database. All data were processed using R software (version 3.5.1) \[[@pone.0211291.ref013]\].

Statistical analysis {#sec004}
--------------------

The expression of *FAM64A* in patients in the TCGA-Liver Hepatocellular Carcinoma (LIHC) dataset was evaluated using box plots. A received operating characteristic (ROC) curve was generated to evaluate the diagnostic value of *FAM64A* expression using the pROC package \[[@pone.0211291.ref014]\], and the area under curve (AUC) of ROC curve represents the diagnostic value. Patients were divided into two groups (high and low *FAM64A* expression) according to the threshold value identified from the ROC curve. The chi-square and Fisher exact tests were applied to identify correlations between *FAM64A* mRNA expression and clinical features of pancreatic cancer. OS and RFS were compared between the high and low *FAM64A* expression groups via Kaplan-Meier analysis, with p-values calculated by the log-rank test, using the Survival package in R \[[@pone.0211291.ref015], [@pone.0211291.ref016]\]. Univariate Cox analysis was performed to select potential prognostic factors, and multivariate Cox analysis was performed to verify the correlations between *FAM64A* expression and survival along with other clinical features. P\<0.05 was considered statistically significant.

GSEA {#sec005}
----

To identify potential mechanisms underlying the influence of *FAM64A* expression on pancreatic cancer prognosis, GSEA was performed to detect whether an a priori defined set of genes showed statistically significant differential expression between the high and low *FAM64A* expression groups \[[@pone.0211291.ref017], [@pone.0211291.ref018]\]. Gene sets with a normal P-value \<0.05 and false discovery rate (FDR) \<0.25 were considered to be significantly enriched.

Results {#sec006}
=======

Characteristics of the study population {#sec007}
---------------------------------------

The clinical data of 179 patients were downloaded from TCGA database, including patients' age, gender, and alcohol consumption history as well as the anatomic location, histological type, histologic grade, clinical stage, TNM classification, residual tumor, therapy, survival status, and recurrence of pancreatic cancer ([Table 1](#pone.0211291.t001){ref-type="table"}).

10.1371/journal.pone.0211291.t001

###### Clinical characteristics of the pancreatic cancer patients.

![](pone.0211291.t001){#pone.0211291.t001g}

  Characteristic                 n (%)
  ------------------------------ ------------
  Age                            
  \<55 years                     34(18.99)
  ≥55 years                      145(81.01)
  Gender                         
  Female                         80(44.69)
  Male                           99(55.31)
  Alcohol consumption history    
  No                             65(36.31)
  Yes                            102(56.98)
  Not available                  12(6.7)
  Anatomic location              
  Head of pancreas               139(77.65)
  Body of pancreas               14(7.82)
  Tail of pancreas               15(8.38)
  Other                          11(6.15)
  Histological type              
  Adenocarcinoma other subtype   26(14.53)
  Adenocarcinoma ductal type     147(82.12)
  Colloid carcinoma              4(2.23)
  Undifferentiated carcinoma     1(0.56)
  Not available                  1(0.56)
  Histological grade             
  G1                             31(17.32)
  G2                             96(53.63)
  G3                             48(26.82)
  G4                             2(1.12)
  GX                             2(1.12)
  Stage                          
  I                              21(11.73)
  II                             147(82.12)
  III                            4(2.23)
  IV                             5(2.79)
  Not available                  2(1.12)
  T classification               
  T1                             7(3.91)
  T2                             24(13.41)
  T3                             143(79.89)
  T4                             3(1.68)
  TX                             1(0.56)
  Not available                  1(0.56)
  N classification               
  N0                             50(27.93)
  N1                             124(69.27)
  NX                             4(2.23)
  Not available                  1(0.56)
  M classification               
  M0                             80(44.69)
  M1                             5(2.79)
  MX                             94(52.51)
  Residual tumor                 
  R0                             107(59.78)
  R1                             53(29.61)
  R2                             5(2.79)
  RX                             4(2.23)
  Not available                  10(5.59)
  Survival status                
  Death                          93(51.96)
  Survival                       86(48.04)
  Recurrence                     
  No                             98(54.75)
  Yes                            58(32.40)
  Not available                  23(12.85)

High *FAM64A* expression in pancreatic cancer {#sec008}
---------------------------------------------

*FAM64A* expression in pancreatic cancer and normal tissues was compared ([Fig 1](#pone.0211291.g001){ref-type="fig"}), and the results indicated that *FAM64A* expression was elevated in pancreatic cancer (P\<2.2e-16). Moreover, differences in *FAM64A* expression were observed according to histological grade (P = 0.029) and survival status (P = 0.0021).

![*FAM64A* expression in pancreatic cancer.\
*FAM64A* expression was compared between normal tissues and pancreatic cancer tissues as well as according to the cancer stage, histologic grade, anatomic location, TNM classification, survival status, sample type, patient age, gender, alcohol consumption history, lymph node positivity, residual tumor, treatment with radiation, and treatment with targeted molecular therapy.](pone.0211291.g001){#pone.0211291.g001}

Diagnostic value of *FAM64A* expression in pancreatic cancer {#sec009}
------------------------------------------------------------

To assess the diagnostic value of *FAM64A*, we generated a ROC curve using the expression data from pancreatic cancer patients and healthy individuals ([Fig 2A](#pone.0211291.g002){ref-type="fig"}). The area under the ROC curve (AUC) was 0.735, which indicated modest diagnostic value. Subgroup analysis demonstrated the diagnostic value of *FAM46A* expression in different stages of pancreatic cancer, with AUC values of 0.619 for stage I disease, 0.755 for stage II disease, 0.688 for stage III disease, and 0.750 for stage IV disease ([Fig 2B--2E](#pone.0211291.g002){ref-type="fig"}).

![Diagnosis value of *FAM64A* expression in pancreatic cancer.\
(A) ROC curve for *FAM64A* expression in normal pancreatic tissue and pancreatic cancer. (B-E) Subgroup analysis for stage I, II, III, and IV pancreatic cancer.](pone.0211291.g002){#pone.0211291.g002}

Correlation between *FAM64A* expression and clinical features of pancreatic cancer {#sec010}
----------------------------------------------------------------------------------

We divided patients into two groups (high versus low *FAM64A* expression) according to the threshold determined from the ROC curve. The associations identified between *FAM64A* expression and the clinical characteristics of pancreatic cancer cases are summarized in [Table 2](#pone.0211291.t002){ref-type="table"}. Survival status (P = 0.0023) and recurrence (P = 0.0376) were significantly correlated with *FAM64A* expression.

10.1371/journal.pone.0211291.t002

###### Relationship between the clinical features of pancreatic cancer and *FAM64A* expression.

![](pone.0211291.t002){#pone.0211291.t002g}

  Features              Variable                       n     *FAM64A* (%)   χ^2^     P                     
  --------------------- ------------------------------ ----- -------------- -------- ---- -------- ------- -----------
  Age                   \<55 years                     34    18             -15.38   16   -25.81   2.224   0.136
                        ≥55 years                      145   99             -84.62   46   -74.19           
  Gender                Female                         80    55             -47.01   25   -40.32   0.487   0.485
                        Male                           99    62             -52.99   37   -59.68           
  Alcohol use history   No                             65    43             -39.81   22   -37.29   0.024   0.878
                        Yes                            102   65             -60.19   37   -62.71           
  Anatomic location     Body of pancreas               14    9              -7.69    5    -8.06    3.288   0.349
                        Head of pancreas               139   88             -75.21   51   -82.26           
                        Other                          11    7              -5.98    4    -6.45            
                        Tail of pancreas               15    13             -11.11   2    -3.23            
  Histological type     Adenocarcinoma Other subtype   26    14             -12.07   12   -19.35   2.319   0.509
                        Adenocarcinoma ductal type     147   98             -84.48   49   -79.03           
                        Colloid carcinoma              4     3              -2.59    1    -1.61            
                        Undifferentiated carcinoma     1     1              -0.86    0    0                
  Histologic grade      G1                             31    16             -13.68   15   -24.19   4.334   0.363
                        G2                             96    65             -55.56   31   -50              
                        G3                             48    33             -28.21   15   -24.19           
                        G4                             2     1              -0.85    1    -1.61            
                        GX                             2     2              -1.71    0    0                
  Stage                 I                              21    12             -10.34   9    -14.75   1.290   0.732
                        II                             147   97             -83.62   50   -81.97           
                        III                            4     3              -2.59    1    -1.64            
                        IV                             5     4              -3.45    1    -1.64            
  T classification      T1                             7     4              -3.45    3    -4.84    3.799   0.434
                        T2                             24    13             -11.21   11   -17.74           
                        T3                             143   97             -83.62   46   -74.19           
                        T4                             3     2              -1.72    1    -1.61            
                        TX                             1     0              0        1    -1.61            
  N classification      N0                             50    38             -32.48   12   -19.67   3.507   0.173
                        N1                             124   77             -65.81   47   -77.05           
                        NX                             4     2              -1.71    2    -3.28            
  M classification      M0                             80    50             -42.74   30   -48.39   0.877   0.645
                        M1                             5     4              -3.42    1    -1.61            
                        MX                             94    63             -53.85   31   -50              
  Residual tumor        R0                             107   68             -62.39   39   -65      0.334   0.954
                        R1                             53    35             -32.11   18   -30              
                        R2                             5     3              -2.75    2    -3.33            
                        RX                             4     3              -2.75    1    -1.67            
  Survival status       Death                          93    71             -60.68   22   -35.48   9.325   **0.002**
                        Survival                       86    46             -39.32   40   -64.52           
  Recurrence            No                             98    55             -56.12   43   -74.14   4.321   **0.038**
                        Yes                            58    43             -43.88   15   -25.86           

Bold values indicate P\<0.05.

High *FAM64A* expression is an independent risk factor for OS among pancreatic cancer patients {#sec011}
----------------------------------------------------------------------------------------------

Kaplan-Meier curves showed that high *FAM64A* expression was associated with worse OS (P = 0.0044; [Fig 3](#pone.0211291.g003){ref-type="fig"}). Subgroup analysis indicated that high *FAM64A* expression significantly affected the OS in pancreatic cancer cases of histological grade G1/G2 (p = 0.0054), clinical stage Ⅰ/Ⅱ (p = 0.0049), and N1 (p = 0.033). Univariate and multivariate Cox analyses showed that *FAM64A* expression was an independent risk factor for OS among pancreatic cancer patients (hazard ratio \[HR\] = 1.87, 95% confidence interval \[CI\]: 1.14--3.06, P = 0.013, [Table 3](#pone.0211291.t003){ref-type="table"}).

![Kaplan-Meier curves for OS in pancreatic cancer.\
Kaplan-Meier curves for OS in pancreatic cancer for all cases and cases of histologic grade G1/G2 and G3/G4; clinical stage Ⅰ/Ⅱ, and Ⅲ/Ⅳ; and TNM classification T1, T2, T3, N0, N1, and M0.](pone.0211291.g003){#pone.0211291.g003}
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###### Univariate analysis and multivariate analysis of the correlation of *FAM64A* expression with OS among pancreatic cancer patients.

![](pone.0211291.t003){#pone.0211291.t003g}

  Parameter             Univariate analysis   Multivariate analysis                                   
  --------------------- --------------------- ----------------------- ----------- ------ ------------ -----------
  Age                   1.22                  0.73--2.05              0.446                           
  Gender                0.81                  0.54--1.22              0.320                           
  Alcohol use history   1.09                  0.79--1.5               0.604                           
  Histological type     2.07                  1.36--3.16              **0.001**   1.71   1.09--2.7    **0.020**
  Histologic grade      1.33                  1.04--1.7               **0.021**   1.18   0.9--1.55    0.223
  Stage                 1.33                  0.96--1.84              0.089                           
  T classification      1.64                  1.08--2.49              **0.021**   1.11   0.68--1.8    0.684
  N classification      1.93                  1.23--3.03              **0.005**   1.58   0.97--2.58   0.064
  M classification      1.13                  0.79--1.64              0.500                           
  Residual tumor        1.36                  1.06--1.76              **0.018**   1.43   1.1--1.86    **0.008**
  *FAM64A*              1.99                  1.23--3.22              **0.005**   1.87   1.14--3.06   **0.013**

Bold values indicate P\<0.05. HR, hazard ratio; CI, confidence interval.

High *FAM64A* expression is an independent risk factor for RFS in pancreatic cancer patients {#sec012}
--------------------------------------------------------------------------------------------

Kaplan-Meier curves for RFS showed that high *FAM64A* expression was associated with poor RFS (P = 0.0041; [Fig 4](#pone.0211291.g004){ref-type="fig"}). Subgroup analysis identified that high *FAM64A* expression correlated significantly with poor RFS in pancreatic cancer cases of histologic grade G1/G2 (p = 0.012), clinical stage Ⅰ/Ⅱ (p = 0.0016), T1 (p = 0.036), T2 (p = 0.0076), and N1 (p = 0.037). Univariate and multivariate Cox analyses confirmed the role of *FAM64A* expression as an independent risk factor for RFS in pancreatic cancer patients (HR = 2.5, 95%CI: 1.36--4.61, P = 0.003, [Table 4](#pone.0211291.t004){ref-type="table"}).

![Kaplan-Meier curves for RFS in pancreatic cancer.\
Kaplan-Meier curves for RFS in all pancreatic cancer cases as well as cases of histologic grade G1/G2 and G3/G4; clinical stage Ⅰ/Ⅱ and Ⅲ/Ⅳ; and TNM classification T1, T2, T3, N0, N1, and M0.](pone.0211291.g004){#pone.0211291.g004}
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###### Univariate analysis and multivariate analysis of the correlation of *FAM64A* expression with RFS among pancreatic cancer patients.

![](pone.0211291.t004){#pone.0211291.t004g}

  Parameter           Univariate analysis   Multivariate analysis                                   
  ------------------- --------------------- ----------------------- ----------- ------ ------------ -----------
  Age                 0.93                  0.51--1.71              0.827                           
  Gender              1.12                  0.67--1.89              0.667                           
  Alcohol history     1.22                  0.79--1.87              0.364                           
  Histological type   1.09                  0.65--1.84              0.733                           
  Histologic grade    1.56                  1.13--2.17              **0.007**   1.51   1.07--2.14   **0.020**
  Stage               1.41                  0.98--2.04              0.064                           
  T classification    1.51                  0.94--2.41              0.088                           
  N classification    2.03                  1.17--3.52              **0.012**   1.87   1.06--3.3    **0.032**
  M classification    1.42                  0.92--2.21              0.116                           
  Residual tumor      1.73                  1.23--2.42              **0.002**   1.87   1.33--2.64   **0.000**
  *FAM64A*            2.34                  1.29--4.26              **0.005**   2.50   1.36--4.61   **0.003**

Bold values indicate P\<0.05. HR, hazard ratio; CI, confidence interval.

GSEA identifies an *FAM64A*-related signaling pathway {#sec013}
-----------------------------------------------------

To identify signaling pathways activated in pancreatic cancer, we performed GSEA comparing the low and high *FAM64A* expression datasets. GSEA revealed significant differences (FDR \<0.25, NOM P-value \<0.05) in the enrichment of MSigDB Collection (h.all.v6.2.symbols.gmt), and the details are provided in [Table 5](#pone.0211291.t005){ref-type="table"}. Gene sets related to mitotic spindles, myc targets, MTORC1 signaling, G2M checkpoint, E2F targets, DNA repair, glycolysis and unfolded protein response were differentially enriched with the high *FAM64A* expression phenotype ([Fig 5](#pone.0211291.g005){ref-type="fig"}).

![Enrichment plots from GSEA.\
GSEA results showing differential enrichment of genes related to mitotic spindles, myc targets, MTORC1 signaling, G2M checkpoint, E2F targets, DNA repair, glycolysis and unfolded protein response in pancreatic cancer cases with high *FAM64A* expression.](pone.0211291.g005){#pone.0211291.g005}
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###### Gene sets enriched in the high *FAM64A* expression phenotype.

![](pone.0211291.t005){#pone.0211291.t005g}

  Gene set name                        NES     NOM p-val   FDR q-val
  ------------------------------------ ------- ----------- -----------
  HALLMARK_MITOTIC_SPINDLE             2.133   0.000       0.018
  HALLMARK_MYC_TARGETS_V2              2.065   0.004       0.016
  HALLMARK_MTORC1_SIGNALING            2.033   0.004       0.012
  HALLMARK_MYC_TARGETS_V1              1.983   0.004       0.015
  HALLMARK_G2M_CHECKPOINT              1.982   0.000       0.012
  HALLMARK_E2F_TARGETS                 1.930   0.000       0.015
  HALLMARK_DNA_REPAIR                  1.928   0.006       0.013
  HALLMARK_GLYCOLYSIS                  1.803   0.000       0.025
  HALLMARK_UNFOLDED_PROTEIN_RESPONSE   1.772   0.049       0.026

NES: normalized enrichment score; NOM: nominal; FDR: false discovery rate. Gene sets with NOM P-value \<0.05 and FDR q-value \<0.25 were considered as significantly enriched.

Discussion {#sec014}
==========

Our study found that the high *FAM64A* expression was associated with poor survival status and recurrence in pancreatic cancer. Kaplan-Meier curves for OS and RFS also showed that higher expression of *FAM64A* was associated with worse outcomes in pancreatic cancer patients. Univariate and multivariate Cox analyses indicated the *FAM64A* mRNA expression may be a useful biomarker for pancreatic cancer prognosis, and ROC analysis confirmed the diagnostic value of *FAM64A* expression in pancreatic cancer.

In the field of oncology, Archangelo et al. first reported the high *FAM64A* expression in hematologic carcinomas, including leukemia and lymphoma \[[@pone.0211291.ref006]\]. However, few studies have investigated *FAM64A* expression in solid tumors. Zhang et al. \[[@pone.0211291.ref011]\] and Yamada et al. \[[@pone.0211291.ref012]\] found that *FAM64A* is upregulated in triple negative breast cancer and renal cell carcinoma, respectively. The present study demonstrated high *FAM64A* expression in pancreatic cancer, which is consistent with other findings for *FAM64A* expression in tumors. ROC analysis provided evidence that *FAM64A* could be developed as a biomarker for the diagnosis of pancreatic cancer, and we found that distinct histologic grades and survival status were associated with *FAM64A* expression, which suggests a possible relationship between *FAM64A* expression and survival in pancreatic cancer.

Many studies have reported that *FAM64A* plays an important role in malignant transformation. Archangelo et al. also found that the expression of *FAM64A* is elevated during mouse embryogenesis \[[@pone.0211291.ref006]\]. Hashimoto et al. showed that knockdown of the *FAM64A* gene in fetal cardiomyocytes leads to repression of cell cycle genes and Ki67 downregulation \[[@pone.0211291.ref019]\]. Barbutti et al. demonstrated that cell proliferation and cell cycle progression are correspondingly reduced upon silencing of *FAM64A* in the U937 cell line or MDA-MB-231 cells \[[@pone.0211291.ref009]\]. Based on these reports, higher expression of *FAM64A* indicates the promotion of cell proliferation, which might contribute to worse outcomes in pancreatic cancer patients. Yamada et al. also demonstrated the value of *FAM64A* expression in the prognosis of breast cancer and renal cell carcinoma \[[@pone.0211291.ref012]\]. Hu et al. explored the prognostic role of *FAM64A* expression in a variety of cancer types, including pancreatic cancer \[[@pone.0211291.ref010]\]. Consistently, our results showed that *FAM64A* expression was correlated with OS in patients with pancreatic cancer, and the potential mechanism may be related with mitotic spindles, myc targets, MTORC1 signaling, G2M checkpoint, E2F targets, DNA repair, glycolysis and unfolded protein response as GSEA identified. In addition, we further explored the prognostic value of *FAM64A* expression in different subgroups of pancreatic cancer and found that high *FAM64A* expression correlated significantly with G1/G2, stage I/II, and N1 cases.

At present, surgery is the only curable treatment for pancreatic cancer \[[@pone.0211291.ref020]\]. However, the possibility of recurrence, which adversely impacts patients' outcomes, is an important factor in the choice of treatment. Here we also explored the correlation of *FAM64A* expression with recurrence, and found that this potential biomarker may help to guide treatment selection in pancreatic cancer patients. High expression of *FAM64A* also negatively affected OS and RFS among patients in with histological grade G1/G2 and clinical stage Ⅰ/Ⅱ cancers, but not with histological grade G3/G4 and clinical stage Ⅲ/Ⅳ cancers, which further demonstrates the specific prognostic role of *FAM64A* expression in subgroup analysis and its potential contribution to precision therapy for pancreatic cancer. However, the reduce number of patients evaluated in the later stages is a limitation in this study, future work need to expend the sample size to verify this conclusion.

Overall, our study provides evidence of the diagnostic and prognostic value of *FAM64A* expression in pancreatic cancer patients. However, the diagnostic and prognostic roles of high *FAM64A* expression were limited to stage Ⅰ and Ⅱ cases, and further identification of effective biomarkers in pancreatic cancer cases of advanced stage is imperative in the future.

Conclusion {#sec015}
==========

Our data demonstrate that *FAM64A* is upregulated in pancreatic cancer, and elevated *FAM64A* expression correlates with clinical progression and serves as an independent risk factor for OS and RFS in pancreatic cancer patients. Our findings suggest that *FAM64A* may be a useful biomarker in the diagnosis and prognosis of pancreatic cancer.
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